@acinvestorblogJan 20, 2026 · 9:01 PM

$CRVS offering Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $22,500,000 of shares of common stock at the public offering price less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

@adamfeuersteinJan 20, 2026 · 12:04 PM

$CRVS Corvus pill shows promise in early-stage eczema trial 75% of participants treated with soquelitinib achieved EASI 75 after 8 weeks compared to 20% of placebo participants offered a placebo. https://t.co/XlOmX0GUZf

@photonbullDec 7, 2025 · 9:08 PM

@retail_mourinho what does RM smell on $CRVS?

@jacobpliethNov 27, 2025 · 1:37 PM

If you need some biotech reading over Thanksgiving check out @ApexOnco previews of #ASH25 --> https://t.co/cqsR1AVbPH Starts in just over a week! $ACLX $ONC $CRVS $TERN $KURA $SNDX $CGEM $INCY